Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HEXA | P06865 | 5/20 | 0.33 |
| ▸ | HEXB | P07686 | 5/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477817 | 0.80 | HEXA (0.35) | HTTHEXAHEXBDHFR | |
| SCHEMBL5481929 | 0.71 | PDE5A (0.34) | HEXAHEXBNPSR1 | |
| SCHEMBL29819457 | 0.70 | KDM4E (0.51) | NSD2CASP6ALDH1A1TP53KDM4E | |
| SCHEMBL6423600 | 0.69 | NSD2 (0.40) | NSD2CASP6L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL8508802 | 0.66 | HTT (0.43) | NSD2CASP6HTTL3MBTL1ALDH1A1 | |
| SCHEMBL12844134 | 0.65 | HEXA (0.37) | HEXAHEXBALDH1A1TP53DHFR | |
| SCHEMBL8720515 | 0.65 | L3MBTL1 (0.52) | NSD2CASP6HTTL3MBTL1ALDH1A1 | |
| SCHEMBL5612938 | 0.65 | NSD2 (0.39) | NSD2CASP6L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL17622541 | 0.64 | MAPK1 (0.48) | HTTALDH1A1KDM4EMAPK1 | |
| SCHEMBL15075241 | 0.63 | ADORA3 (0.44) | HEXAHEXBDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20050010047-A1 | Pteridinone derivatives as modulators of chemokine receptor activity | BONNERT ROGER VICTOR (GB) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010047-A1 | Pteridinone derivatives as modulators of chemokine receptor activity | CCR5, CXCR3, CCR2 | NSD2 3302/4885CASP6 4525/4885HTT 4699/4885 |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | CCR5, CXCR3, CCR2 | NSD2 3302/4885CASP6 4525/4885HTT 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.